pravastatin has been researched along with pravastatin sodium in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blankley, CJ; Krause, BR; Newton, RS; Picard, JA; Roark, WH; Roth, BD; Sekerke, C; Shaw, MK; Sliskovic, DR; Stanfield, RL | 1 |
| Draper, CD; Hutson, JL; Inglis, GG; Procopiou, PA; Ross, BC; Watson, NS | 1 |
| Fujikawa, Y; Iwasaki, H; Kitahara, M; Sakashita, M; Sakoda, R; Suzuki, M | 1 |
3 other study(ies) available for pravastatin and pravastatin sodium
| Article | Year |
|---|---|
Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.
Topics: Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry, Physical; Cholesterol; Dogs; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Molecular Structure; Pravastatin; Pyrazines; Pyrazoles; Pyridines | 1992 |
Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Carcinoma, Hepatocellular; Cholesterol; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors.
Topics: Administration, Oral; Animals; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |